Myriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing
26 September 2016 - 9:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular
diagnostics and personalized medicine, today announced it will
present three new studies at the National Society of Genetic
Counselors Annual Education Conference being held Sept. 28-Oct. 1,
2016 in Seattle, Washington.
“We are excited to be co-sponsoring the 35th National Society of
Genetic Counselors Annual Education Conference,” said Susan Manley,
L.C.G.C., M.B.A., vice president of Medical Services, Myriad
Genetic Laboratories. “We’re looking forward to presenting
important new scientific data, which will improve the practice of
genetic counseling. We also are excited to host a patient
advocacy event in conjunction with the Conference, which will help
raise funds for important patient advocacy groups including Be the
Difference Foundation, Hereditary Colon Cancer Foundation and
Li-Fraumeni Syndrome Association.”
Below is a list of the featured presentations at NSGC
(#NSGC16):
Poster Presentations
- Title: Average Age of Diagnosis of Ovarian
Cancer for Women with Pathogenic Variants in BRIP1, RAD51C and
RAD51D.Presenter: Susana San
Roman.Date: Friday, September 30, 2016: 11:30
am – 12:45 pm PT.Poster: C-117.
- Title: Ancestry-Based Cancer Risks Associated
with APC I1307K.Presenter: Lavania
Sharma.Date: Friday, September 30, 2016: 11:30 am
– 12:45 pm PT.Poster: C-123.
- Title: Psychosocial Outcomes of Identifying
High or Moderate Risk Mutation Carriers by Hereditary Cancer Panel
Testing.Presenter: Julie
Culver.Date: Thursday, September 29, 2016:
5:45 pm – 7:00 pm PT.Poster: B-71.
For more information about these presentations, including a
complete list of abstracts and presentations, please visit the NSGC
website at http://nsgc.org/p/cm/ld/fid=423.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
three strategic imperatives: transitioning and expanding its
hereditary cancer testing markets, diversifying its product
portfolio through the introduction of new products and increasing
the revenue contribution from international markets. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary
Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx,
myChoice HRD, Vectra and Prolaris are trademarks or registered
trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G
Safe Harbor StatementThis press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements relating to the Company presenting three new studies at
the National Society of Genetic Counselors Annual Education
Conference being held Sept. 28-Oct. 1, 2016 in Seattle, Washington;
presenting important new scientific data, which will improve the
practice of genetic counseling; hosting a patient advocacy event in
conjunction with the Conference, which will help raise funds for
important patient advocacy groups including Be the Difference
Foundation, Hereditary Colon Cancer Foundation and Li-Fraumeni
Syndrome Association; and the Company’s strategic directives under
the caption “About Myriad Genetics.” These “forward-looking
statements” are based on management’s current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those described or implied in the
forward-looking statements. These risks and uncertainties include,
but are not limited to: the risk that sales and profit margins of
our existing molecular diagnostic tests and pharmaceutical and
clinical services may decline or will not continue to increase at
historical rates; risks related to our ability to transition from
our existing product portfolio to our new tests, including
unexpected costs and delays; risks related to changes in the
governmental or private insurers’ reimbursement levels for our
tests or our ability to obtain reimbursement for our new tests at
comparable levels to our existing tests; risks related to increased
competition and the development of new competing tests and
services; the risk that we may be unable to develop or achieve
commercial success for additional molecular diagnostic tests and
pharmaceutical and clinical services in a timely manner, or at all;
the risk that we may not successfully develop new markets for our
molecular diagnostic tests and pharmaceutical and clinical
services, including our ability to successfully generate revenue
outside the United States; the risk that licenses to the technology
underlying our molecular diagnostic tests and pharmaceutical and
clinical services tests and any future tests are terminated or
cannot be maintained on satisfactory terms; risks related to delays
or other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire, including but not limited to our acquisition of a
healthcare clinic in Germany and Sividon Diagnostic and our planned
acquisition of Assurex Health; risks related to our projections
about our business, results of operations and financial condition;
risks related to the potential market opportunity for our products;
the risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents; risks related to changes in
intellectual property laws covering our molecular diagnostic tests
and pharmaceutical and clinical services and patents or enforcement
in the United States and foreign countries, such as the Supreme
Court decision in the lawsuit brought against us by the Association
for Molecular Pathology et al; risks of new, changing and
competitive technologies and regulations in the United States and
internationally; and other factors discussed under the heading
“Risk Factors” contained in Item 1A of our Annual report on Form
10-K for the fiscal year ended June 30, 2015, which has been filed
with the Securities and Exchange Commission, as well as any updates
to those risk factors filed from time to time in our Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K.
Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024